Literature DB >> 27526705

Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance.

Mitchell H Rosner1, Amaka Edeani2, Motoko Yanagita3, Ilya G Glezerman4,5, Nelson Leung6,7.   

Abstract

Paraprotein-related kidney disease represents a complex group of diseases caused by an abnormal paraprotein secreted by a clone of B cells. The disease manifestations range from tubulopathies, such as the Fanconi syndrome, to a spectrum of glomerular diseases that can present with varying degrees of proteinuria and renal dysfunction. Diagnosis of these diseases can be challenging because of the wide range of manifestations as well as the relatively common finding of a serum paraprotein, especially in elderly patients. Thus, renal biopsy along with detailed hematologic workup is essential to link the presence of the paraprotein to the associated renal disease. Recent advances in treatment with more effective and targeted chemotherapies, as well as stem cell transplantation, have improved the renal and overall prognosis for many of these disorders.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  Aged; B-Lymphocytes; Biopsy; Fanconi Syndrome; Humans; Kidney Diseases; Paraproteins; Prognosis; Stem Cell Transplantation; kidney; kidney disease; monoclonal gammopathy; multiple myeloma; paraproteinemia; proteinuria

Mesh:

Year:  2016        PMID: 27526705      PMCID: PMC5142062          DOI: 10.2215/CJN.02920316

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  68 in total

1.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

2.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

3.  Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.

Authors:  Sandra M S Herrmann; Morie A Gertz; Mark D Stegall; Angela Dispenzieri; Fernando C Cosio; Shaji Kumar; Martha Q Lacy; Patrick G Dean; Mikel Prieto; Steven R Zeldenrust; Francis K Buadi; Stephen J Russell; Scott L Nyberg; Suzanne R Hayman; David Dingli; Fernando C Fervenza; Nelson Leung
Journal:  Nephrol Dial Transplant       Date:  2011-05-04       Impact factor: 5.992

4.  Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation.

Authors:  K Weichman; L M Dember; T Prokaeva; D G Wright; K Quillen; M Rosenzweig; M Skinner; D C Seldin; V Sanchorawala
Journal:  Bone Marrow Transplant       Date:  2006-07-24       Impact factor: 5.483

5.  Paraffin immunofluorescence in the renal pathology laboratory: more than a salvage technique.

Authors:  Nidia C Messias; Patrick D Walker; Christopher P Larsen
Journal:  Mod Pathol       Date:  2015-02-13       Impact factor: 7.842

6.  Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein.

Authors:  C Cameron Yin; Pei Lin; Dennis A Carney; Beverly C Handy; George Z Rassidakis; Joan H Admirand; Michael J Keating; L Jeffrey Medeiros
Journal:  Am J Clin Pathol       Date:  2005-04       Impact factor: 2.493

7.  Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Authors:  G Palladini; P Milani; A Foli; M Vidus Rosin; M Basset; F Lavatelli; M Nuvolone; L Obici; S Perlini; G Merlini
Journal:  Leukemia       Date:  2014-07-25       Impact factor: 11.528

8.  Nephrotoxic potential of Bence Jones proteins.

Authors:  A Solomon; D T Weiss; A A Kattine
Journal:  N Engl J Med       Date:  1991-06-27       Impact factor: 91.245

Review 9.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

10.  Screening panels for detection of monoclonal gammopathies.

Authors:  Jerry A Katzmann; Robert A Kyle; Joanne Benson; Dirk R Larson; Melissa R Snyder; John A Lust; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Clin Chem       Date:  2009-06-11       Impact factor: 8.327

View more
  13 in total

1.  Monoclonal Gammopathies and Kidney Disease: Searching for Significance.

Authors:  Christina Hao Wang; Jonathan J Hogan
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-15       Impact factor: 8.237

2.  Paraprotein-Related Kidney Disease: Attack of the Killer M Proteins.

Authors:  Mark A Perazella; Kevin W Finkel
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-07       Impact factor: 8.237

3.  Monoclonal gammopathy of renal significance presenting as monotypic plasma cell interstitial nephritis in two patients with Sjögren's syndrome.

Authors:  Arzu Saglam; Seda Balaban; Tolga Yıldırım; Yunus Erdem; Aysegul Uner; Yahya Büyükaşık
Journal:  Virchows Arch       Date:  2017-11-16       Impact factor: 4.064

4.  What is the place of POEMS syndrome in the current classification of monoclonal gammopathies of renal significance?

Authors:  Mariana Ciocchini; Carlos Guido Musso
Journal:  Int Urol Nephrol       Date:  2017-11-13       Impact factor: 2.370

5.  Association of Monoclonal Gammopathy with Progression to ESKD among US Veterans.

Authors:  Nicholas Burwick; Scott V Adams; Jeffrey A Todd-Stenberg; Nilka Rios Burrows; Meda E Pavkov; Ann M O'Hare
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-15       Impact factor: 8.237

6.  The light at the end of the tunnel: an unusual case of acute kidney injury in a pediatric patient: Answers.

Authors:  Miriam Steinberg; Joseph P Gaut; Stanley Paul Hmiel; Aadil Kakajiwala
Journal:  Pediatr Nephrol       Date:  2018-03-09       Impact factor: 3.714

Review 7.  The Scope of Kidney Affection in Monoclonal Gammopathies at All Levels of Clinical Significance.

Authors:  Şadiye Mehtat Ünlü; Hayri Özsan; Sülen Sarıoğlu
Journal:  Turk J Haematol       Date:  2017-08-23       Impact factor: 1.831

8.  Legionella Pneumonia Complicated with Acquired Fanconi Syndrome.

Authors:  Ryo Koda; Ryo Itoh; Masafumi Tsuchida; Kazumasa Ohashi; Noriaki Iino; Toshinori Takada; Ichiei Narita
Journal:  Intern Med       Date:  2018-06-06       Impact factor: 1.271

9.  A Single-Center Retrospective Study to Investigate the Follow-Up of Patients with Monoclonal Proteinemia by Community Physicians in the UK.

Authors:  Indra Ramasamy
Journal:  J Blood Med       Date:  2020-06-11

10.  Successful Renal Outcome in Membranoproliferative Glomerulonephritis Following Treatment of the Underlying Subtle Clone: A Case Report.

Authors:  Ritika Rana; Paul Cockwell; Bindu Vydianath; Mark Cook; Guy Pratt; Mark Trehane Drayson; Jennifer Helen Pinney
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2018-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.